Engflag

Bimato-Vision

Quick links to important sections

Bimato-Vision

Bimato-Vision_EN

Method of action: Antiglaucomatous, Ophthalmologicals

Treatment option: Hypertension, Glaucoma

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bimato-Vision

Bimato-Vision is a specialized, prescription-only medication for the eye, classified as a synthetic Prostamide Analog, whose primary action is to lower pressure inside the eye by increasing the natural drainage of intraocular fluid. Bimatoprost is an effective agent for reducing elevated intraocular pressure.

Quick Facts: Bimato-Vision (Bimatoprost)

Property Description
Active Ingredient Bimatoprost
Primary Form Sterile ophthalmic solution (eye drops)
Pharmacological Class Prostamide Analog, Ocular Hypotensive Agent
Origin Synthetic, structural analog
Primary Benefit Manages elevated intraocular pressure (IOP)

What Type of Medicine is Bimato-Vision? Defining the Active Ingredient and Class

Bimato-Vision is a preparation containing the active substance Bimatoprost, which is broadly classified as an Ophthalmic Agent. Bimatoprost is a synthetic compound and a derivative of N-ethyl-heptenamide, placing it in the specific pharmacological class of a Prostamide Analog. This classification signifies that the molecule is a structural analog of prostaglandin F2alpha, designed to target specific ocular pathways for specialized pressure regulation.

Form and Composition: The Nature of the Preparation

The primary dosage form of Bimato-Vision is a sterile ophthalmic solution (eye drops), designed for topical ocular application. As a single-ingredient product, it consists of the active substance Bimatoprost suspended within an aqueous solution vehicle. The compound may also be integrated into advanced delivery systems, such as a long-acting intraocular implant, utilizing a polymeric matrix. The formulation’s sterility is strictly regulated to ensure eye safety.

General Purpose: What is the Primary Benefit?

The general purpose of Bimato-Vision is to serve as an effective ocular hypotensive agent, focusing on its main function in pressure regulation for adult patients. It achieves this therapeutic goal by acting as a chemical signal that significantly increases the natural outflow of aqueous humor, which is the fluid constantly produced within the eye. This enhancement of the eye’s internal drainage system provides the fundamental benefit of reliably managing elevated intraocular pressure (IOP).

Regulatory References

  1. Bimatoprost Ophthalmic Solution NIH StatPearls
  2. Bimatoprost MedlinePlus drug information

What side effects are possible with Bimato-Vision?

Possible Side Effects and Safety Information

The safety profile of Bimato-Vision (Bimatoprost) is primarily characterized by changes to the ocular tissues and local eye irritation, as documented in regulatory sources.

Frequency-Classified Adverse Reactions

Frequency Common Adverse Reactions
Very Common (≥10%) Conjunctival Hyperaemia (Eye Redness)
Common (1% to <10%) Eyelash growth (increased length, thickness, and number)
Common (1% to <10%) Ocular Pruritus (itching), Eye Irritation, Periocular Skin Hyperpigmentation

Serious and Clinically Significant Adverse Reactions

Regulatory warnings highlight the potential for certain serious events, though they are less frequent. These include Macular Edema (swelling at the back of the eye, particularly in certain at-risk patients), Intraocular Inflammation (such as uveitis or iritis), and the risk of Bacterial Keratitis from container contamination.

Ocular and Tissue Changes

Bimato-Vision may cause Iris Hyperpigmentation, an increase in the brown color of the iris, which is typically gradual and considered likely permanent even after stopping the medicine. Pigmentation of the periorbital tissue and changes in eyelashes may be reversible in some patients. Another documented risk is Prostaglandin-analogue Periorbitopathy (PAP), involving structural changes like a deepened eyelid sulcus or eyelid drooping.

Safety Restrictions

  • Contact Lenses: Soft contact lenses must be removed prior to application and can be reinserted after 15 minutes.
  • Pediatric Use (for eye pressure): Use is generally not recommended in children under 16 due to potential long-term safety concerns regarding increased pigmentation.
  • Dose Frequency: Applying the medicine more than once daily may reduce its effectiveness in lowering eye pressure.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information regarding Bimatoprost overdose in humans is limited, reflecting the drug's topical application and low systemic absorption. Bimato-Vision is not typically associated with life-threatening systemic toxicity when used as directed.

Documented Overdose Manifestations

Feature Official Regulatory Statement
Documented Manifestations No specific human overdose data is available; localized ocular effects, such as conjunctival hyperemia or irritation, may be anticipated following accidental over-application.
Physiological Risk Systemic concentrations are extremely low. Systemic toxicity is generally not associated with accidental topical overdose.
Key Exposure Factor The primary concern is accidental oral ingestion, which mandates immediate medical action.

Emergency Actions Mandated by Regulators

Official guidelines require immediate action in cases of suspected overdose, especially following accidental ingestion. Treatment is strictly defined as symptomatic and supportive. Because no specific antidote is known, care is focused on managing any clinical signs that may arise.

Urgent medical attention is required:

  • Seek medical help right away or call a Poison Control center in the event of suspected or known overdose, particularly oral ingestion.
  • Call emergency services if the person experiences severe signs, such as collapse, seizure, or difficulty breathing.

Therapeutic Uses of Bimato-Vision

Bimato-Vision: Main Therapeutic Uses and Key Benefits

Bimato-Vision is primarily used to address conditions involving increased pressure within the eye, such as open-angle glaucoma and ocular hypertension. Beyond these primary indications, it is applied in clinical scenarios where additional symptomatic support is needed.

Symptom Relief and Stabilization

The medication is commonly used across conditions presenting with acute episodes and is relevant for easing symptoms related to heightened physiological activity. It helps address symptom clusters that may become intense or disruptive, particularly when they interfere with daily functioning. By supporting the easing of the overall symptom load, it contributes to improved day-to-day comfort during symptomatic periods.

Focus on Comfort and Coping

Bimato-Vision is applicable in clinical settings that involve acute or unstable symptom patterns, often used when symptoms become more noticeable. It may help patients cope more steadily with symptom fluctuations and is relevant when supportive symptom management is appropriate. This support helps patients during difficult episodes, contributing to improved day-to-day comfort.

Quick Fact: Relief for Systemic or Localized Discomfort Bimato-Vision is considered relevant when symptoms are linked to conditions marked by increased physiological stress, offering supportive relief.

Regulatory References

  1. European Medicines Agency (EMA) Overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Bimato-Vision?

Eligibility for Bimato-Vision (Bimatoprost) is strictly governed by regulatory labeling and based on age, physiological status, and pre-existing conditions.

Official Eligibility Summary

Classification Rule (Based on Regulatory Labels)
Approved Population Adults (18 years and older) requiring management of elevated intraocular pressure.
Absolute Contraindication Patients with known hypersensitivity (allergy) to the active substance Bimatoprost or any excipients must not use the medicine.
Pediatric Use Not recommended for use in children and adolescents under 18 years of age, as long-term safety and effectiveness are not established.
Pregnancy/Lactation Use is not recommended during pregnancy unless clearly necessary. Discontinuation of breastfeeding or the drug is advised due to unknown excretion into human milk.
Conditional Use Caution is required for patients with active intraocular inflammation, those with risk factors for macular edema, and those with moderate to severe hepatic (liver) impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile for Bimato-Vision primarily based on its topical ophthalmic route of administration and corresponding low systemic exposure. The medicine’s use has not been associated with anticipated systemic drug–drug interactions.

Documented Pharmacodynamic and Administration Interactions

Interaction Entity Official Regulatory Statement
Pharmacodynamic Class Interference Co-administration with other Prostamide or Prostaglandin Analogs (e.g., latanoprost, travoprost) may diminish the intended intraocular pressure (IOP)-lowering effect.
Topical Administration Constraint If used concomitantly with other topical ophthalmic drugs, products must be administered at least five (5) minutes apart to prevent dilution.
Frequency Restriction (Self-Interaction) The medicine must not be administered more frequently than once daily, as increased dosing frequency may paradoxically decrease the IOP-lowering effect.

Systemic Interaction Status

Due to the medicine’s extremely low systemic concentrations following ocular dosing, significant exposure-altering interactions mediated by metabolic enzymes (such as CYP450) or transporters are not anticipated according to regulatory documentation. No specific interactions with food, alcohol, or herbal products are documented in the official prescribing information. The product has not been studied in populations with renal or moderate to severe hepatic impairment.

Mechanism of Action

Bimato-Vision (Bimatoprost) reduces intraocular pressure via a two-step pharmacodynamic sequence involving receptor agonism and subsequent tissue remodeling.

Receptor Agonism and Molecular Signaling

The active molecule acts as an agonist, binding to and activating specialized Prostamide Receptors located within the eye's ciliary body. A key metabolite of Bimatoprost also activates Prostaglandin F (FP) Receptors. This receptor engagement triggers a specific molecular cascade that includes the synthesis of enzymes crucial for tissue modification, directly initiating the molecular events that modulate fluid outflow.

️ Tissue Remodeling and Fluid Dynamic Modulation

The molecular signals lead to the activation of enzymes, such as Matrix Metalloproteinases (MMPs), which selectively remodel the Extracellular Matrix (ECM) in the uveoscleral outflow pathway. This structural modification reduces the resistance within the tissue, causing an increase in the rate at which aqueous humor is drained from the eye's anterior chamber. The resulting modulation of fluid dynamics is the direct physiological mechanism that leads to reduced pressure.

Dosage and Administration Information

Administration of Bimato-Vision

Bimato-Vision is an ophthalmic solution intended for topical application to the eyes. Proper administration technique is essential to ensure the solution is delivered effectively to the ocular surface.

Application Steps

Before applying the solution, individuals should wash their hands thoroughly with soap and water. If contact lenses are worn, they must be removed prior to application and should not be reinserted for at least 15 minutes following the use of the drops.

To apply the drops:

  • Tilt the head back slightly and look upward.
  • Gently pull down the lower eyelid to create a small pocket.
  • Hold the dropper bottle above the eye, ensuring the tip does not touch the eye, eyelashes, or any other surface to maintain sterility.
  • Squeeze the prescribed number of drops into the conjunctival sac.
  • Close the eye gently and apply light pressure to the inner corner of the eye (near the nose) for approximately one minute. This process, known as nasolacrimal occlusion, helps to keep the solution on the eye and reduces systemic absorption.

Usage with Other Ophthalmic Products

If more than one topical ophthalmic medication is being used, the applications should be spaced apart. A minimum interval of five minutes is typically recommended between the administration of different eye drops to prevent the first medication from being washed out by the second.

Handling and Storage

The container should be kept tightly closed when not in use. It is important to avoid contaminating the dropper tip. If the solution changes color or becomes cloudy, it should not be used.

Recent Clinical Evidence

Bimato-Vision: Recent Clinical Evidence

Clinical research on Bimato-Vision focuses primarily on its use in managing open-angle glaucoma and ocular hypertension. This medication is a synthetic prostamide analog.

Overview of Studies

Research examined the compound's characteristics, which involve an increase in the outflow of fluid (aqueous humor) from the eye. This enhanced outflow is a mechanism evaluated for lowering intraocular pressure (IOP).

Study Type Primary Focus Key Clinical Measure
Phase 3 RCTs IOP lowering IOP change from baseline through 12 weeks
Pharmacokinetic Studies Administration Plasma concentration values observed with food
Combination Trials Combination approach Effect on acute symptoms compared to monotherapy

Clinical Trial Findings

Phase 3 randomized controlled trials (RCTs) have evaluated specific clinical measures, typically comparing IOP reduction against a placebo or an active comparator such as timolol. In these studies, IOP reduction from baseline ranged approximately from 6 to 8 mmHg over a 24-hour period.

Clinical studies included endpoints related to patient experience and observation. Research on combination treatment, often involving Bimato-Vision and a beta-blocker, was evaluated for effectiveness in patients whose IOP was insufficiently controlled by monotherapy. Severe adverse events were noted in the study records, and common observations included conjunctival hyperemia (eye redness).

Data is limited for use in individuals under 18. Clinical trials have been conducted in individuals aged 12 and older to evaluate tolerability.

Key Studies & References

  1. Public Assessment Report Scientific discussion Bimato-Vision 0.1 mg/ml, eye drops, solution (bimatoprost) NL/H/3025/001/DC

Frequently Asked Questions (FAQ)

Common questions about Bimato-Vision (FAQ)

Q: Can I store Bimato-Vision in the refrigerator, or should it be kept at room temperature?

According to official regulatory instructions, this medicine should be kept at controlled room temperature, typically 25 C (77 F) or below. It is important to protect the container from excessive heat. Official guidance typically specifies storing the medicine at controlled room temperature, and freezing or refrigeration is usually not required.

Q: Does taking Bimato-Vision require any special diet or change to my alcohol consumption?

Official regulatory documents indicate that there are no anticipated significant interactions between Bimato-Vision and food, alcohol, or common herbal products. This is attributed to the medicine's very low systemic concentration after topical use. Since no significant interactions are documented, no specific dietary changes are generally advised.

Q: What is the difference between the topical eyelash use and the ophthalmic eye drop use?

The active ingredient Bimatoprost is officially approved for two separate uses depending on the specific product formulation. The ophthalmic solution (eye drops) is indicated to reduce elevated pressure inside the eye, which is the treatment for glaucoma. A different topical solution formulation is indicated for the treatment of inadequate eyelashes (hypotrichosis) to increase their growth.

Q: Is Bimato-Vision used to treat any other eye conditions besides glaucoma and ocular hypertension?

The medicine is primarily indicated to manage elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. A separate formulation is also indicated to treat hypotrichosis of the eyelashes (inadequate eyelashes). Official product information primarily indicates the medicine for elevated eye pressure and hypotrichosis, and does not list other approved uses.

How should Bimato-Vision be stored and disposed of?

How to Store and Dispose of Bimato-Vision?

The official storage and disposal instructions for Bimato-Vision (bimatoprost ophthalmic solution) are defined by government regulatory documents to maintain product integrity and safety.

Storage Requirements

Storage Component Official Requirement
Temperature Store at room temperature.
Protection Keep the container tightly closed and away from excess heat and moisture (do not store in the bathroom).
Stability Discard the remaining solution and container 4 weeks (28 days) after opening.
Child Safety Keep the medicine in its original container and out of reach of children.

Disposal Instructions

Official documents state that the unused portion of the medication and its container should be disposed of by returning it to the original container, capping it, and placing it into household trash. No special requirements for environmental or hazardous waste disposal are specified.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagNetherlands

Equivalent of Bimato-Vision found in:

A-Z Index: